Most notably, recent findings leveraging in vivo measurements of peripheral glial fibrillary acidic protein (GFAP), a strong correlate of astrocyte activation, found that high plasma GFAP expression, representing a greater degree of astrocyte reactivity, relates to higher AD neuropathological burden [3, 29]. This evidence concerns the gene GFAP and Alzheimer disease.